3Olanow C W.The role of dopamine agonists in the treatment of early Parkinson's disease[J].Neurology,2002,58(1):33.
4Sorbera L A,Martin L.Etilevodopa.Antiparkinsonian dopamine precursor[J].Drugs Future,2001,26(3):219.
5Jankovic J.Levodopa strengths and weaknesses[J].Neurology,2002,58(4):s19.
6Jenner P.Pharmacology of dopamine agonists in the treatment of Parkinson's disease[J].Neurology,2002,58(4,Supp.1):S1.
7Negrotti A,Bizzarri G,Calzetti S.Long-term persistence of symptomatic effect of selegiline in Parkinson's disease.A two-months placebo controlled withdrawal study[J].J Neural Transm,2001,108(2):215.
8Rabey J M,Sagi I,Huberman M,et al.Rasagiline mesylate,a new mao-B inhibitor for the treatment of Parkinson's disease;a doubleblind study as adjunctive therapy to levodopa Clin[J].Neuropharmacology,2000,23(6):324.
